Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: Implications for diseases in the cardiovascular system

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 3, 2007, Pages

  Berndt, Carsten ^a   Lillig, Christopher Horst ^a,b   Holmgren, Arne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Apoptotic signaling; Glutathione; Myocardial remodeling; Oxidative stress; Thiol disulfide oxidoreductases

Indexed keywords

AMINO ACID DERIVATIVE; APOPTOSIS SIGNAL REGULATING KINASE 1; BINDING PROTEIN; CISTEINYLPROLYLTYROSYLCYSTEINE; CISTEINYLSERYLTYROSYLCYSTEINE; CYSTEINYLGLYCYLPROLYLCYSTEINE; GLUTAREDOXIN; GLUTATHIONE; GLUTATHIONE REDUCTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THIOL DERIVATIVE; THIOREDOXIN; THIOREDOXIN BINDING PROTEIN 2; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

APOPTOSIS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL GROWTH; DISEASE COURSE; ELECTRON TRANSPORT; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; HEART; HUMANS; OXIDOREDUCTASES; SIGNAL TRANSDUCTION; SULFHYDRYL COMPOUNDS; THIOREDOXIN;

EID: 33847746679     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01162.2006     Document Type: Review

References (156)

1. Adachi T, Pimentel DR, Heibeck T, Hou X, Lee YJ, Jiang B, Ido Y, Cohen RA. S-glutathionylation of ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells. J Biol Chem 279: 29857-29862, 2004.
2. Ago T, Sadoshima J. Thioredoxin and ventricular remodeling. J Mol Cell Cardiol 41: 762-773, 2006.
3. Akamatsu Y, Ohno T, Hirota K, Kagoshima H, Yodoi J, Shigesada K. Redox regulation of the DNA binding activity in transcription factor PEBP2. The roles of two conserved cysteine residues. J Biol Chem 272: 14497-14500, 1997.
4. Anversa P, Cheng W, Liu Y, Leri A, Redaelli G, Kajstura J. Apoptosis and myocardial infarction. Basic Res Cardiol 93: 8-12, 1998.
5. Aota M, Matsuda K, Isowa N, Wada H, Yodoi J, Ban T. Protection against reperfusion-induced arrhythmias by human thioredoxin. J Cardiovasc Pharmacol 27: 727-732, 1996.
6. Bandyopadhyay S, Starke DW, Mieyal JJ, Gronostajski RM. Thioltransferase (glutaredoxin) reactivates the DNA-binding activity of oxidation-inactivated nuclear factor I. J. Biol Chem 273: 392-397, 1998.
7. Barett WC, DeGnore JP, Konig S, Fales HM, Keng YF, Zhang ZY, Yim MB, Chock PB. Regulation of PTP1B via glutathionylation of the active site cysteine 215. Biochemistry 38: 6699-6705, 1999.
8. Beer SM, Taylor ER, Brown SE, Dahm CC, Costa NJ, Runswick MJ, Murphy MP. Glutaredoxin 2 catalyses the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins. J Biol Chem 279: 47939-47951, 2004.
9. Berndt C, Hudemann C, Hanschmann EM, Axelsson R, Holmgren A, Lillig CH. How does iron-sulfur cluster coordination regulate the activity of human glutaredoxin 2? Antioxid Redox Signal 9: 151-157, 2007.
10. -/- mice. J Clin Invest 108: 1513-1522, 2001.
11. Billiet L, Furman C, Larigauderi G, Copin C, Brand K, Fruchart JC, Rouis M. Extracellular human thioredoxin-1 inhibits lipopolysaccharide- induced interleukin-1beta expression in human monocyte-derived macrophages. J Biol Chem 280: 40310-40318, 2005.
12. Bjornstedt M, Xue J, Huang W, Akesson B, Holmgren A. The thioredoxin and glutaredoxin systems are efficient electron donors to human plasma glutathione peroxidase. J Biol Chem 269: 29382-29384, 1994.
13. Bodenstein J, Follmann H. Characterization of two thioredoxins in pig heart including a new mitochondrial protein. Z Naturforsch [C] 46: 270-279, 1991.
14. Brot N, Weissbach H. Biochemistry and physiological role of methionine sulfoxide residues in proteins. Arch Biochem Biophys 223: 271-281, 1983.
15. Bushweller JH, Aslund F, Wüthrich K, Holmgren A. Structural and functional characterization of the mutant Escherichia coli glutaredoxin (C14 - S) and its mixed disulfide with glutathione. Biochemistry 31: 9288-9293, 1992.
16. Byler RM, Sherman NA, Wallner JS, Horrwitz LD. Hydrogen peroxide cytotoxicity in cultured cardiac myocytes is iron dependent. Am J Physiol Heart Circ Physiol 266: H121-H127, 1994.
17. Chrestensen CA, Starke DW, Mieyal JJ. Acute cadmium exposure inactivates thioltransferase (glutaredoxin) inhibits intracellular reduction of protein-glutathionyl-mixed disulfides and initiates apoptosis. J Biol Chem 275: 26556-26565, 2000.
18. Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW, Brielmeier M. Essential role for mitochondrial thioredoxin reductase in hematopoiesis heart development and heart function. Mol Cell Biol 24: 9414-9423, 2004.
19. Daily D, Vlamis-Gardikas A, Offen D, Mittelmann L, Melamed E, Holmgren A, Barzilai A. Glutaredoxin protects cerebellar granulae neurons from dopamine-induced apoptosis by dual activation of the Ras-phosphoinositide 3-kinase and Jun N-terminal kinase pathway. J Biol Chem 276: 21618-21626, 2001.
20. Daily D, Vlamis-Gardikas A, Offen D, Mittelmann L, Melamed E, Holmgren A, Barzilai A. Glutaredoxin protects cerebellar granulae neurons from dopamine-induced apoptosis by activating NF-kappaB via Ref-1. J Biol Chem 276: 1335-1344, 2001.
21. Das D. Thioredoxin regulation of ischemic preconditioning. Antioxid Redox Signal 6: 405-412, 2004.
22. Das D, Engelman RM, Kimura Y. Molecular adaption of cellular defenses following preconditioning of the heart by repeated ischemia. Cardiovasc Res 27: 578-584, 1993.
23. Davies SW, Duffy JP, Wickens DG, Underwood SM, Hill A, Alladine MF, Feneck RO, Dormandy TL, Walesby RK. Time-course of free radical activity during coronary artery operations with cardiopulmonary bypass. J Thorac Cardiovasc Surg 105: 979-987, 1993.
24. Davis DA, Newcomb FM, Starke DW, Ott DE, Mieyal JJ, Yarchoan R. Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro. J Biol Chem 272: 25935-42590, 1997.
25. Dobsak P, Siegelova J, Wolf JE, Rochette L, Eicher JC, Vasku J, Kuchtickova S, Horky M. Prevention of apoptosis by deferoxamine during 4 hours of cold cardioplegia and reperfusion: in vitro study of isolated working rat heart model. Pathophysiology 9: 27-32, 2002.
26. Dwivedi VK, Chandra M, Misra PC, Misra A, Misra MK. Status of some free radical scavenging enzymes in the blood of myocardial infarction patients. J Enzyme Inhib Med Chem 21: 43-46, 2006.
27. Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, Lips DJ, Doevendans PA. Role of apoptosis in reperfusion injury. Cardiovasc Res 61: 414-426, 2004.
28. Engström NE, Holmgren A, Larsson A, Söderhäll S. Isolation and characterization of calf liver thioredoxin. J Biol Chem 249: 205-210, 1974.
29. Enoksson M, Fernandes AP, Prast S, Lillig CH, Holmgren A, Orrenius S. Overexpression of glutredoxin 2 attenuates apoptosis by preventing cytochrome c release. Biochem Biophys Res Commun 327: 774-779, 2005.
30. Ferdinandy P, Schulz R. Nitric oxide superoxide and peroxynitrite in myocardial ischemia-reperfusion injury and preconditioning. Br J Pharmacol 138: 532-543, 2003.
31. Fernandes AP, Fladvad M, Berndt C, Andresen C, Lillig CH, Neubauer P, Sunnerhagen M, Holmgren A, Vlamis-Gardikas A. A novel monothiol glutaredoxin (GRX4) from Escherichia coli can serve as a substrate for thioredoxin reductase. J Biol Chem 280: 24544-24552, 2005.
32. Francis GS. Pathophysiology of chronic heart failure. Am J Med 110: 37S-46S, 2001.
33. Furman C, Rundlof AK, Larigauderie G, Jaye M, Bricca G, Copin C, Kandoussi AM, Fruchart JC, Arner ES, Rouis M. Thioredoxin reductase 1 is upregulated in atherosclerotic plaques: specific induction of the promotor in human macrophages by oxidized low-density lipoproteins. Free Radic Biol Med 37: 71-85, 2004.
34. Galaris D, Barbouti A, Korantzopoulos P. Oxidative stress in hepatic ischemia-reperfusion injury: the role of antioxidants and iron chelating compounds. Curr Pharm Des 12: 2875-2890, 2006.
35. Gladyshev VN, Jeang KT, Stadtman TC. Selenocysteine identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase corresponds to TGA in the human placental gene. Proc Natl Acad Sci USA 93: 6146-6151, 1996.
36. Gladyshev VN, Liu A, Novoselov SV, Krysan K, Sun QA, Kryukov VM, Kryukov GV, Lou MF. Identification and characterization of a new mammalian glutaredoxin (thioltransferase) GRX2. J Biol Chem 276: 30374-30380, 2001.
37. Gravina SA, Mieyal JJ. Thioltransferase is a specific glutathionyl mixed disulfide oxidoreductase. Biochemistry 32: 3368-3376, 1993.
38. Griendling KK, Fitzgerald GA. Oxidative stress and cardiovascular injury. Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108: 1912-1916, 2003.
39. Grippo JF, Holmgren A, Pratt WB. Proof that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin. J Biol Chem 260: 93-97, 1985.
40. Gutteridge JMC, Halliwell B. Reoxigenation injury and antioxidant protection: a tale of two paradoxes. Arch Biochem Biophys 283: 223-226, 1990.
41. Hagg D, Englund MC, Jernas M, Schmidt C, Wiklund O, Hulten LM, Ohlsson BG, Carlsson LM, Carlsson B, Svensson PA. Oxidized LDL induces a coordinated up-regulation of the glutathione and thioredoxin systems in human macrophages. Atherosclerosis 185: 282-289, 2006.
42. Hayashi S, Hajiro-Nakanishi K, Makino Y, Eguchi H, Yodoi J, Tanaka H. Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Nucleic Acids Res 25: 4035-4040, 1997.
43. Hayashi T, Uedo Y, Okamato T. Oxidoreductive regulation of nuclear factor kappa-B. Involvement of a cellular reducing catalyst thioredoxin. J Biol Chem 268: 11380-11388, 1993.
44. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 94: 3633-3638, 1997.
45. Hirota K, Matsui M, Murata M, Takashima Y, Cheng FS, Itoh T, Fukuda K, Yodoi J. Nucleoredoxin glutaredoxin and thioredoxin differentially regulate NF-kappaB AP-1 and CREB activation in HEK293 cells. Biochem Biophys Res Commun 274: 177-182, 2000.
46. 2-terminal kinase activation via a glutathione reductase-mediated mechanism. Circ Res 91: 712-718, 2002.
47. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 264: 13963-13966, 1989.
48. Holmgren A. Hydrogen donor system for Escherichia coli ribonucleoside-diphosphate reductase dependent upon glutathione. Proc Natl Acad Sci USA 73: 2275-2279, 1976.
49. Holmgren A. Glutathione-dependent enzyme reactions of the phage T4 ribonucleotide reductase system. J Biol Chem 253: 7424-7430, 1978.
50. Holmgren A. Glutathione-dependent synthesis of deoxyribonucleotides. Characterisation of the enzymatic mechanism of Escherichia coli glutaredoxin. J Biol Chem 254: 3672-3678, 1979.
51. Holmgren A. Thioredoxin. Annu Rev Biochem 54: 237-271, 1985.
52. Holmgren A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure 3: 239-243, 1995.
53. Holmgren A, Luthman M. Tissue distribution and subcellular localization of bovine thioredoxin determined by radioimmunoassay. Biochemistry 17: 4071-4077, 1978.
54. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y. Induction of apoptosis by ASK1 a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275: 90-94, 1997.
55. Ide T, Tsutsui H, Kinugawa S, Suematsu N, Hayashidani S, Ichikawa K, Utsumi H, Machida Y, Egashira K, Takeshita A. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myorardium. Circ Res 86: 152-157, 2000.
56. Jakupoglu C, Przemeck GK, Schneider M, Moreno SG, Mayr N, Hatzopoulos AK, de Angelis MH, Wurst W, Bornkamm GW, Brielmeier M, Conrad M. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol Cell Biol 25: 1980-1988, 2005.
57. Jekell A, Hossain A, Alehagen U, Dahlstrom U, Rosen A. Elevated circulating levels of thioredoxin and stress in chronic heart failure. Eur J Heart Fail 6: 883-890, 2004.
58. Jeong D, Cha H, Kim E, Kang M, Yang DK, Kim JM, Yoon YO, Oh JG, Bernecker OZ, Sakata S, Thu LT, Cui L, Lee YH, Kim DH, Woo SH, Liao R, Hajjar RJ, Park WJ. PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomycyte contractility. Circulation 99: 307-314, 2006.
59. Johansson C, Lillig CH, Holmgren A. Human mitochondrial glutaredoxin reduces S-glutathionylated proteins with high affinity accepting electrons from either glutathione or thioredoxin reductase. J Biol Chem 279: 7537-7543, 2004.
60. 3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 164: 6287-6295, 2000.
61. Kallis GB, Holmgren A. Differential reactivity of the functional sulfhydryl groups of cysteine-32 and cysteine-35 present in the reduced form of thioredoxin from Escherichia coli. J Biol Chem 255: 10261-10265, 1980.
62. Kirklin JW, Barratt-Boyes BG. Cardiac Surgery (2nd ed.). New York: Churchill Livingston, 1993, p. 61-128.
63. Kishimoto C, Shioji K, Nakamura H, Nakayama Y, Yodoi J, Sasayama S. Serum thioredoxin (TRX) levels in patients with heart failure. Jpn Circ J 65: 491-494, 2001.
64. Klatt P, Pineda-Molina E, de Lacoba MG, Padilla AC, Martinez-Galisteo E, Barzena JA, Lamas S. Redox regulation of c-Jun DNA binding by reversible S-glutathionylation. FASEB J 13: 1481-1490, 1999.
65. Knowlton KV, Badorff C. The immune system in viral myocarditis: maintaining the balance. Circ Res 99: 559-561, 1999.
66. Kurooka H, Kato K, Minoguchi S, Takahashi Y, Ikeda J, Habu S, Osawa N, Buchberg AM, Moriwaki K, Shisa H, Honjo T. Cloning and characterization of the nucleoredoxin gene that encodes a novel nuclear protein related to thioredoxin. Genomics 39: 331-339, 1997.
67. Kuster GM, Pimentel DR, Adachi T, Ido Y, Brenner DA, Cohen RA, Liao R, Siwik DA, Colucci WS. Alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on Ras. Circulation 111: 1192-1198, 2005.
68. Laurent TC, Moore EC, Reichard P. Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin the hydrogen donor from Escherichia coli. J Biol Chem 239: 3436-3444, 1964.
69. Lee KK, Murakawa M, Takahashi S, Tsubuki S, Kawashima S, Sakamaki K, Yonehara S. Purification molecular cloning and characterization of TRP32 a novel thioredoxin-related mammalian protein of 32 kDa. J Biol Chem 273: 19160-19166, 1998.
70. Lesnefsky EJ. Tissue iron overload and mechanisms of iron-catalyzed oxidative injury. Adv Exp Med Biol 366: 129-146, 1994.
71. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in servere chronic heart failure. N Engl J Med 323: 236-341, 1990.
72. Li GC, Vasquez BS, Gallagher KP, Lucchesi BR. Myocardial protection with preconditioning. Circulation 82: 609-619, 1990.
73. Lillig CH, Berndt C, Vergnolle O, Lönn ME, Hudemann C, Bill E, Holmgren A. Characterization of human glutaredoxin 2 as iron-sulfur protein: a possible role as redox sensor. Proc Natl Acad Sci USA 102: 8168-8173, 2005.
74. Lillig CH, Lönn ME, Enoksson M, Fernandes AP, Holmgren A. Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells towards doxorubicin and phenylarsine oxide. Proc Natl Acad Sci USA 101: 13227-13232, 2004.
75. Lind C, Gerdes R, Schuppe-Koistinen I, Cotgreave IA. Studies on the mechanism of oxidative modification of human glyceraldehyde-3-phosphate dehydrogenase by glutathione: catalysis by glutaredoxin. Biochem Biophys Res Commun 247: 481-486, 1998.
76. Lundberg M, Fernandes AP, Kumar S, Holmgren A. Cellular and plasma levels of human glutaredoxin 1 and 2 detected by sensitive ELISA systems. Biochem Biophys Res Commun 319: 801-809, 2004.
77. Lundberg M, Johansson C, Chandra J, Enoksson M, Jacobsson G, Ljung J, Johansson M, Holmgren A. Cloning and expression of a novel human glutaredoxin (GRX2) with mitochondrial and nuclear isoforms. J Biol Chem 276: 26269-26275, 2001.
78. Lundstrom-Ljung J, Holmgren A. Glutaredoxin accelerates glutathione-dependent folding of reduced ribonuclease A together with protein disulfide-isomerase. J Biol Chem 270: 7822-7828, 1995.
79. Luthman M, Holmgren A. Rat liver thioredoxin and thioredoxin reductase: Purification and characterization. Biochemistry 21: 6628-6633, 1982.
80. Luyten CR, van Overveld FJ, De Backer LA, Sadowski AM, Rodrigus IE, De Hert SG, De Backer WA. Antioxidant defence during cardiopulmonary bypass surgery. Eur J Cardiothorac Surg 27: 611-616, 2005.
81. Martin JL. Thioredoxin - a fold for all reasons. Structure 3: 245-250, 1995.
82. Masutani H, Hirota K, Sasada T, Ueda-Taniguchi Y, Taniguchi Y, Sono H, Yodoi J. Transactivation of an inducible anti-oxidative stress protein human thioredoxin by HTLV-I Tax. Immunol Lett 54: 67-71, 1996.
83. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-kappa-B by reducing a disulfide bond involving cysteine 62. Nucleic Acids Res 20: 3821-3830, 1992.
84. Maulik N, Sasaki H, Addya S, Das D. Differential regulation of BCL-2 AP-1 and NF-kB on cardiomyocyte apoptosis during myocardial ischemic stress adaption. FEBS Lett 443: 331-336, 2000.
85. Maulik N, Sato M, Price BD, Das D. An essential role of NFkB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaption to ischemia. FEBS Lett 429: 365-369, 1998.
86. Meyer EB, Wells WW. Thioltransferase overexpression increases resistance of MCF-7 cells to adriamycin. Free Radic Biol Med 26: 770-776, 1999.
87. Miranda-Vizuete A, Sadek CM, Jimenez A, Krause WJ, Sutovsky P, Oko R. The mammalian testis-specific thioredoxin system. Antioxid Redox Signal 6: 25-40, 2004.
88. Miyamoto M, Kishimoto C, Nimata M, Nakamura H, Yodoi J. Thioredoxin a redox-regulating protein is expressed in spontanous myocarditis in inbred strains of mice. Int J Cardiol 95: 315-319, 2004.
89. Miyamoto M, Kishimoto C, Shioji K, Nakamura H, Toyokuni S, Nakayama Y, Kita M, Yodoi J, Sasayama S. Difference in thioredoxin expression in viral myocarditis in inbred strains of mice. Jpn Circ J 65: 561-564, 2001.
90. Molina-Navarro MM, Casas C, Piedrafita L, Belli G, Herrero E. Prokaryotic and eukaryotic monothiol glutaredoxins are able to perform the functions of Grx5 in the biogenesis of Fe/S clusters in yeast mitochondria. FEBS Lett 580: 2273-2280, 2006.
91. Mühlenhoff U, Gerber J, Richhardt N, Lill R. Components involved in assembly and dislocation of iron-sulfur clusters on the scaffold protein Isu1p. EMBO J 22: 4815-4825, 2003.
92. Murray CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986.
93. Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio G, Imamura M, Takabayashi A, Yamaoka Y, Yodoi J. Expression of thioredoxin and glutaredoxin redox regulating proteins in pancreatic cancer. Cancer Detect Prev 24: 53-60, 2000.
94. Nakamura H, Vaage J, Valen G, Padilla CA, Bjornstedt M, Holmgren A. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. Free Radic Biol Med 24: 1176-1186, 1998.
95. Nakamura T, Ohno T, Hirota K, Nishiyama A, Nakamura H, Wada H, Yodoi J. Mouse glutaredoxin - cDNA cloning high level expression in E. coli and its possible implication in redox regulation of the DNA binding activity in transcription factor PEBP2. Free Radic Res 31: 357-365, 1999.
96. Nishida K, Otsu K. The role of apoptosis signal-regulating kinase 1 in cardiomycyte apoptosis. Antioxid Redox Signal 8: 1729-1736, 2006.
97. 3 up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274: 21645-21650, 1999.
98. Nonn L, Williams RR, Erickson RP, Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis exencephaly and early embryonic lethality in homozygous mice. Mol Cell Biol 23: 916-922, 2003.
99. Okuda M, Inoue N, Azumi H, Seno T, Sumi Y, Hirata KI, Kawashima S, Hayashi Y, Itoh H, Yodoi J, Yokoyama M. Expression of glutaredoxin in human coronary arteries: its potential role in antioxidant protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21: 1483-1487, 2001.
100. Onody A, Zvara A, Hackler L, Vigh L Jr, Ferndinandy P, Puskas LB. Effect of classic preconditioning on the gene expression pattern of rat hearts: a DNA microarray study. FEBS Lett 536: 35-40, 2003.
101. Pan J, Singh US, Takahashi T, Oka Y, Palm-Leis A, Herbelin BS, Baker KM. PKC mediates cyclic stretch-induced cardiac hypertrophy through rho family GTPases and mitogen-activated protein kinases in cardiomyocytes. J Cell Physiol 202: 536-553, 2005.
102. Park EM, Thomas JA. The mechanisms of reduction of protein mixed disulfides (dethiolation) in cardiac tissue. Arch Biochem Biophys 274: 47-54, 1989.
103. Pineda-Molina E, Klatt P, Vazquez J, Martina A, de Lacoba MG, Perez-Sala D, Lamas S. Glutathionylation of the p50 subunit of NF-kappaB: a mechanism for redox-induced inhibition of DNA binding. Biochemistry 40: 14134 -14142, 2001.
104. Ramlawi B, Feng J, Mieno S, Szabo C, Zsengeller Z, Clements R, Sodha N, Boodhwani M, Bianchi C, Sellke FW. Indices of apoptosis activation after blood cardioplegia and cardiopulmonary bypass. Circulation 114, Suppl 1: I257-I263, 2006.
105. Reddy S, Jones AD, Cross CE, Wong PSY, van der Vliet A. Inactivation of creatine kinase by S-glutathionylation of the active-site cysteine residue. Biochem J 347: 824-827, 2000.
106. Rhee SG, Chae HY, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543-1552, 2005.
107. Rodriguez-Manzaneque MT, Tamarit J, Belli G, Ros J, Herrero E. Grx5 is a mitochondrial glutaredoxin required for the activity of iron/sulfur enzymes. Mol Biol Cell 13: 1109-1121, 2002.
108. Ross R. Atheriosclerosis: an inflammatory disease. N Engl J Med 340: 115-126, 1999.
109. Rubartelli A, Bajetto A, Allavena G, Wollman E, Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem 267: 24161-24164, 1992.
110. Ruoppolo M, Lundstrom-Ljung J, Talamo F, Pucci P, Marino G. Effect of glutaredoxin and protein disulfide isomerase on the glutathione-dependent folding of ribonuclease A. Biochemistry 36: 12259-12267, 1997.
111. Sadoshima J. Redox regulation of growth and death in cardiac myocytes. Antioxid Redox Signal 8: 1621-1624, 2006.
112. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998.
113. Salvyre R, Auge N, Benoist H, Negre-Salvyre A. Oxidized low-density lipoprotein-induced apoptosis. Arch Biochem Biophys 1585: 213-221, 2002.
114. Sato M, Cordis GA, Maulik N, Das D. SAPKs regulation of ischemic preconditioning. Am J Physiol Heart Circ Physiol 279: H901-H907, 2000.
115. Schafer FQ, Buettner GR. Inhibition of cell growth in: cell and tissue culture. Free Radic Biol Med 30: 238-239, 2001.
116. Schulze PC, Yoshida J, Takahashi T, He Z, King GL, Lee RT. Hyperglycemia promotes oxidative through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 279: 30369-30374, 2004.
117. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, Yodoi J. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 106: 1403-1409, 2002.
118. Shioji K, Kishimoto C, Nakamura H, Toyokuni S, Nakayama Y, Yodoi J, Sasayama S. Upregulation of thioredoxin (TRX) expression in giant cell myocarditis in rats. FEBS Lett 472: 109-113, 2000.
119. 2. J Biol Chem 277: 46566-46575, 2002.
120. Spyrou G, Enmark E, Miranda-Vizuete A, Gustafsson J. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem 272: 2936-2941, 1997.
121. Srinivasan U, Mieyal PA, Mieyal JJ. pH profiles indicative of rate-limiting nucleophilic displacement in thioltransferase catalysis. Biochemistry 36: 3199-3206, 1997.
122. Takashima Y, Hirota K, Nakamura H, Nakamura T, Akiyama K, Cheng FS, Maeda M, Yodoi J. Differential expression of glutaredoxin and thioredoxin during monocytic differentiation. Immunol Lett 68: 397-401, 1999.
123. Tao L, Gao E, Bryan NS, Qu Y, Liu HR, Hu A, Christopher TA, Lopez BL, Yodoi J, Koch W, Feelisch M, Ma XL. Cardioprotective effects of thioredoxin in myocardial ishemia and reperfusion: role of S-nitration. Proc Natl Acad Sci USA 101: 11471-11476, 2004.
124. Tao L, Gao E, Hu A, Coletti C, Wang Y, Christopher TA, Lopez BL, Koch W, Ma XL. Thioredoxin reduces post-ischemic myocardial apoptosis by reducing oxidative/nitrative stress. Br J Pharmacol 149: 311-318, 2006.
125. Tao L, Jiao X, Gao E, Lau WB, Yuan Y, Lopez B, Christopher T, Rao SPR, Williams W, Southan G, Sharma K, Koche W, Ma XL. Nitrative inactivation of thioredoxin-1 and its role in postischemic myocardial apoptosis. Circulation 114: 1395-1402, 2006.
126. Taylor ER, Hurrell F, Shannon RJ, Lin TK, Hirst J, Murphy MP. Reversible glutathionylation of complex I increases mitochondrial superoxide formation. J Biol Chem 278: 19603-19611, 2003.
127. Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 18: 677-685, 1998.
128. Tsutsui H, Ide T, Kinugawa S. Mitochondrial oxidative stress DNA damage and heart failure. Antioxid Redox Signal 8: 1737-1744, 2006.
129. Turoczi T, Chang VW, Engelman RM, Maulik N, Ho YS, Das DK. Thioredoxin redox signaling in the ischemic heart: an insight with transgenic mice overexpressing Trx1. J Mol Cell Cardiol 35: 695-704, 2003.
130. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274: 35809-35815, 1999.
131. Van Driest SL, Gakh O, Ommen SR, Isaya G, Ackerman MJ. Molecular and functional characterization of a human frataxin mutation found in hypertrophiy cardiomyopathy. Mol Genet Metab 85: 280-285, 2005.
132. Vlad M, Caseanu E, Uza G, Petrescu M. Concentration of copper zinc chromium iron and nickel in the abdominal aorta of patients deceased with coronary heart diseas. J Trace Elem Electrolytes Health Dis 8: 111-114, 1994.
133. Wahlgren CM, Pekkari K. Elevated thioredoxin after angioplasty in peripheral arterial disease. Eur J Vasc Endovasc Surg 29: 281-286, 2005.
134. Wang J, Boja ES, Tan W, Tekle E, Fales HM, English S, Mieyal JJ, Chock PB. Reversible glutathionylation regulates actin polymerization in A431 cells. J Biol Chem 276: 47763-47766, 2001.
135. 3-up- regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem 277: 26496-26500, 2002.
136. Wells WW, Xu DP, Yang YF, Rocque PA. Mammalian thioltransferase (glutaredoxin) and protein disulfide isomerase have dehydroascorbate reductase activity. J Biol Chem 265: 15361-15364, 1990.
137. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62: 5089-5095, 2002.
138. Wingert RA, Galloway JL, Barut B, Foott H, Fraenkel P, Axe JL, Weber GJ, Dooley K, Davidson AJ, Schmid B, Paw BH, Shaw GC, Kingsley P, Palis J, Schubert H, Chen O, Kaplan J, Zon LI, Tubingen Screen Consortium. Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature 436: 1035-1039, 2005.
139. Witte S, Villalba M, Bi K, Liu Y, Isakov N, Altman A. Inhibition of the c-Jun N-terminal kinase/AP-1 and NF-kappaB pathways by PICOT a novel protein kinase C-interacting protein with a thioredoxin homology domain. J Biol Chem 275: 1902-1909, 2000.
140. Xiao L, Pimental DR, Amin JK, Sawyer DB, Colucci WS. MEK1/2-ERK1/2 mediates alpha1-adrenergic-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 33: 779-787, 2001.
141. 1- adrenoreceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 282: C926-C934, 2002.
142. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vatner SF, Sadoshima J. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 112: 1395-1406, 2003.
143. Yamanaka H, Maehira F, Oshiro M, Asato T, Yanagawa Y, Takei H, Nakashima Y. A possible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast two-hybrid system. Biochem Biophys Res Commun 271: 796-800, 2000.
144. Yamawaki H, Haendeler J, Berk BC. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res 93: 1029-1033, 2003.
145. Yamawaki H, Lehoux S, Berk BC. Chronic physiological shear stress inhibits tumor necrosis factor-induced proinflammatory responses in rabbit aorta perfused ex vivo. Circulation 108: 1619-1625, 2003.
146. Yamawaki H, Pan S, Lee RT, Berk BC. Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cell. J Clin Invest 115: 733-738, 2005.
147. Yang Y, Jao S, Nanduri S, Starke DW, Mieyal JJ, Qin J. Reactivity of the human thioltransferase (glutaredoxin) C7S C25S C78S C82S mutant and NMR solution structure of its glutathionyl mixed disulfide intermediate reflect catalytic specificity. Biochemistry 37: 17145-17156, 1998.
148. Yoshioka J, Schulze C, Cupesi M, Sylvan JD, MacGillivray C, Gannon J, Huang H, Lee RT. Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity. Circulation 109: 2581-2586, 2004.
149. Yoshitake S, Nanri H, Fernando MR, Minakami S. Possible differences in the regenerative roles played by thioltransferase and thioredoxin for oxidatively damaged proteins. J Biochem 116: 42-46, 1994.
150. You SA, Wang Q. Ferritin in atherosclerosis. Clin Chim Acta 357: 1-16, 2005.
151. Yuan XM, Anders WL, Olsson AG, Brunk UT. Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis 124: 61-73, 1996.
152. Zech B, Wilm M, van Eldik R, Bruhne B. Mass spectrometry analysis of nitric oxide-modified caspase-3. J Biol Chem 274: 20931-20936, 1999.
153. Zhang R, Al-Lamki R, Bai L, Streb JW, Miano JM, Bradley J, Min W. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ Res 94: 1483-1491, 2004.
154. Zhong L, Arnér ESJ, Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc Natl Acad Sci USA 97: 5854-5859, 2000.
155. Zweier JL, Fertmann J, Wei G. Nitric oxide and peroxynitrite in postischemic myocardium. Antioxid Redox Signal 3: 11-12, 2001.
156. Zweier JL, Flaherty JT, Weisfeld ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci USA 84: 1404-1407, 1987.